Commercial Interests at AACR 2017 - A 1stOncology Insights Report - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Commercial Interests at AACR 2017 - A 1stOncology Insights Report" report to their offering.

This report is a unique guide to understanding and evaluating the positions of the cancer drugs and companies presented at the AACR 2017 Annual Meeting.

This leading event in the oncology drug developers calendar represents some of the very best in cancer science and this report allows the reader to review the meeting through the lens of 17 hot areas in oncology. As such, it is a must read for anyone with an interest in oncology and who wants a full picture of the landscape of drug development emerging from AACR 2017.

With more than 6,500+ abstracts presented at AACR 2017, this report allows you to break down this mountain of information to reveal the positions of the more than 470 commercial drugs with published abstracts by their own innovating companies or partners.

These drugs represent the core of what is happening in cancer drug development today and this report reveals where they are positioned in 17 "hot" areas in oncology, including:

- Start-Up

- Fierce 15 Drugs

- Orphan Drugs

- Breakthrough Therapies

- Cancer Vaccines

- CAR/TCR Therapies

- Immune Checkpoints

- Epigenetic Therapies

- Protein Kinase Inhibitors

- Antibodies in Oncology

- Cancer Peptides

- Nucleic Acid Therapies

- Conjugated Drugs

The AACR Annual Meeting is one of the events that shapes the direction of commercial drug development in oncology. Use this report to understand from a trustworthy third-party the position, strengths, weaknesses and recent successes and failures of the drugs represented at this years meeting in an executive and easy to understand format.

Key Topics Covered:

1 Executive Summary

2 About 1stOncology Insights

3 Table of Contents

4 Major Recent Developments on Cancer Drugs at AACR from 2016 to Present

5 Overview of Cancer Drugs at AACR 2017

6 AACR 2017 by Startups

7 AACR 2017 by Fierce 15 Companies

8 AACR 2017 by Orphan Drugs

9 AACR 2017 by Breakthrough Therapies

10 AACR 2017 by Cancer Vaccines

11 AACR 2017 by CAR/TCR Therapies

12 AACR 2017 by Immune Checkpoint Drugs

13 AACR 2017 by Epigenetic Therapies

14 AACR 2017 by DNA Damage Response Drugs

15 AACR 2017 by Protein Kinase Inhibitors

16 AACR 2017 by Antibody Drugs

17 AACR 2017 by Peptide Drugs

18 AACR 2017 by Nucleic Acid Therapies

19 AACR 2017 by Conjugated Drugs

20 Disclaimer

21 Drug Index

22 Drug Innovator Index

For more information about this report visit http://www.researchandmarkets.com/research/qvrhd4/commercial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology